Careers that change lives start here. Medtronic is a global leader in healthcare technology with a Mission to alleviate pain, restore health, and extend life. Our 95,000 employees work across more than 150 countries to put patients first — developing innovative medical technologies that improve the lives of 72+ million patients each year. Your unique talents will help shape the future of healthcare while building a career grounded in purpose, growth, and impact.

A Day in the Life

Responsibilities may include the following and other duties may be assigned.

· Develops and communicates the strategic, financial, and administrative implications of proposed and implemented pricing policies for the PVH Vascular portfolio; translates business strategy, market conditions, and customer needs into clear pricing direction.

· Owns portfolio pricing strategy and governance, including price recommendations, pricing guardrails, approval pathways, exception criteria, and ongoing policy compliance across relevant products, customer types, and market segments.

· Recommends pricing and reimbursement positions for current and future products; evaluates market research, competitive offers, customer economics, contract history, and financial analyses to support sustainable growth and margin.

· Provides pricing input to new-product and launch plans, including launch price architecture, price menus, floors, and negotiation guidance; assesses competitive positioning and price implications for new products.

· Serves as the field- and customer-facing commercial lead for the PVH Commercial Account Desk, owning supply-chain price, terms, and commercial negotiations after the field representative qualifies the opportunity and makes a warm handoff.

· Acts as the single customer-facing commercial lead on price discussions; partners with representatives so they remain focused on physician engagement, clinical adoption, education, case support, utilization, and reorders.

· Applies a consistent qualification gate and deal-routing approach, coordinating central support for enterprise, IDN/GPO, RFP, multi-district, and exception opportunities; district-aligned support for standard hospital deals; and streamlined handling of repeat or standard business within approved floors.

· Negotiates within approved price bands, floors, and trade-off authority; documents rationale and customer commitments; escalates exceptions and material risks through established governance, including the Pricing Board when appropriate.

· Partners with Enterprise Contracting through a defined interface, service levels, shared operating cadence, and escalation path. Provides qualified deal information and negotiation outcomes; does not recreate Contracting analyses or assume its contract drafting, legal redlines, execution, or price-loading responsibilities.

· Provides input on final pricing contracts and coordinates with Contracting, Finance, Legal, Sales, Marketing, and other stakeholders to support accurate, timely, and policy-compliant deal execution.

· Tracks and communicates performance measures such as negotiated price versus approved floor, quote-to-signature cycle time, handoff acceptance, approved-deal execution, customer and field experience, and adoption or reorder outcomes; uses results to improve policy and process.

· Leads day-to-day operation and continuous improvement of the Commercial Account Desk operating model, tools, training, and processes; may guide or coach desk colleagues and cross-functional partners.

Must Have:

High School Diploma or equivalent with 8+ years of relevant experience in pricing, contracts, commercial negotiations, or equivalent experience; OR Associate’s Degree with 6+ years of relevant experience; OR Bachelor’s Degree with 4+ years of relevant experience.

Nice to Have:

· Demonstrated knowledge of pricing strategy, price governance, contract economics, financial analysis, and the customer and market factors that affect price realization.

· Strong negotiation, customer relationship, and executive communication skills, including the ability to lead sensitive supply-chain discussions and communicate pricing decisions with clarity and professionalism.

· Experience partnering across Sales, Marketing, Finance, Legal, and Contracting; skilled at defining handoffs, service levels, escalation paths, and shared measures without duplicating partner responsibilities.

· Strong project and process leadership skills, including stakeholder alignment, change management, training, and continuous improvement. Experience with Salesforce or similar CRM and pricing/contracting systems is beneficial.

For Baccalaureate degrees earned outside of the United States, a degree that satisfies the requirements of 8 C.F.R. § 214.2(h)(4)(iii)(A) is required.

Physical Job Requirements

The above statements are intended to describe the general nature and level of work being performed by employees assigned to this position, but they are not an exhaustive list of all the required responsibilities and skills of this position. 

The physical demands described within the Responsibilities section of this job description are representative of those that must be met by an employee to successfully perform the essential functions of this job. Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions. For Office Roles: While performing the duties of this job, the employee is regularly required to be independently mobile. The employee is also required to interact with a computer, and communicate with peers and co-workers. Contact your manager or local HR to understand the Work Conditions and Physical requirements that may be specific to each role.

U.S. Work Authorization & Sponsorship

At Medtronic, we are committed to fostering an environment where employees can thrive and make a meaningful impact. In alignment with our enterprise-wide workforce planning approach, U.S. work authorization sponsorship (H-1B, TN, J, etc.) is offered exclusively for Principal-level roles and above, where specialized expertise aligns with long-term business needs. Roles below the Principal level require candidates to possess unrestricted U.S. work authorization at the time of hire and for the duration of employment.

‌

Recruitment Fraud Alert

We are aware of phishing scams targeting job seekers. Please keep the following in mind:

Apply only through official Medtronic channels. All legitimate Medtronic recruiting communications come from approved Medtronic platforms and official @medtronic.com email addresses.

Medtronic will never ask for payment or sensitive personal information (such as bank account or Social Security details) during early stages of the hiring process. Any such requests are not legitimate.

If you receive a suspicious message claiming to be from Medtronic, do not respond, click links, or open attachments.

If you have any questions, concerns regarding the authenticity of a communication alleged to have been made by or on behalf of Medtronic, please contact us immediately at [email protected].

‌

Benefits & Compensation

Medtronic offers a competitive Salary and flexible Benefits Package
A commitment to our employees lives at the core of our values. We recognize their contributions. They share in the success they help to create.We offer a wide range of benefits, resources, and competitive compensation plans designed to support you at every career and life stage.

Salary ranges for U.S (excl. PR) locations (USD):$110,400.00 - $165,600.00

‌

This position is eligible for a short-term incentive called the Medtronic Incentive Plan (MIP).The base salary range is applicable across the United States, excluding Puerto Rico and specific locations in California. The offered rate complies with federal and local regulations and may vary based on factors such as experience, certification/education, market conditions, and location. Compensation and benefits information pertains solely to candidates hired within the United States (local market compensation and benefits will apply for others).

The following benefits and additional compensation are available to those regular employees who work 20+ hours per week: Health, Dental and vision insurance,Health Savings Account,Healthcare Flexible Spending Account,Life insurance, Long-term disability leave,Dependent daycare spending account,Tuition assistance/reimbursement, andSimple Steps (global well-being program).

The following benefits and additional compensation are available to all regular employees:Incentive plans, 401(k) plan plus employer contribution and match,Short-term disability,Paid time off,Paid holidays,Employee Stock Purchase Plan,Employee Assistance Program,Non-qualified Retirement Plan Supplement (subject to IRS earning minimums), andCapital Accumulation Plan (available to Vice Presidents and above, or subject to IRS earning minimums).

Regular employees are those who are not temporary, such as interns. Temporary employees are eligible for paid sick time, as required under applicable state law, and the Employee Stock Purchase Plan. Please note some of the above benefits may not apply to workers in Puerto Rico.

Further details are available at the link below:

Medtronic benefits and compensation plans

It is the policy of Medtronic to provide equal employment opportunity (EEO) to all persons regardless of age, color, national origin, citizenship status, physical or mental disability, race, religion, creed, gender, sex, sexual orientation, gender identity and/or expression, genetic information, marital status, status with regard to public assistance, veteran status, or any other characteristic protected by federal, state or local law. In addition, Medtronic will provide reasonable accommodations for qualified individuals with disabilities.

If you are applying to perform work for Medtronic, Inc. (“Medtronic”) in any position which will involve performing at least two (2) hours of work on average each week within the unincorporated areas of Los Angeles County, you can find here a list of all material job duties of the specific job position which Medtronic reasonably believes that criminal history may have a direct, adverse and negative relationship potentially resulting in the withdrawal of a conditional offer of employment. Medtronic will consider for employment qualified job applicants with arrest or conviction records in accordance with the Los Angeles County Fair Chance Ordinance for Employers and the California Fair Chance Act.

About the company

Medtronic makes medical devices and therapies to treat chronic diseases, including implantables, sensors, and diabetes management tools. Its devices interact with the body to regulate or monitor functions, such as pacemakers delivering heart stimulation and neuromodulation devices sending electrical signals. The company differentiates itself through a long history of device development and a broad portfolio, expanded via acquisitions to access new technologies and markets. Its goal is to improve patient health outcomes by providing integrated medical technologies that help manage chronic conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Fridley, Minnesota

Founded

1949

Get referred to Medtronic

See people who can refer or advise you

Simplify's Take

What believers are saying

Sept. 23, 2026 fiscal Q1 organic revenue rose 13.7%, led by Cardiac Ablation Solutions.
Sept. 30, 2026 Affera clearances deepen Medtronic's edge in pulsed field ablation.
Sept. 14, 2026 MiniMed exchange offer advances portfolio simplification and capital redeployment.

What critics are saying

July 15, 2026 Bio-Medicus recall exposed packaging failures in a high-risk perfusion product.
Medtronic spinal cord stimulator cases remain individual, and Schiltz's July 14, 2026 order tightens deadlines.
MiniMed separation still consumes management attention, and a weak public debut pressures execution through 2027.

What makes Medtronic unique

Sep 30, 2026 Prism-2 software tightly links Medtronic catheters, mapping, and PFA therapy.
Sept. 16, 2026 Hugo gained LigaSure robotic clearance, building a multi-platform surgical stack.
Oct. 1, 2026 Altaviva and Symplicity earned Category I CPT codes, accelerating reimbursement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
401(k) Company Match

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth

Medtronic

Oct 29th, 2026

Medtronic completes acquisition of Intersect ENT

Acquisition adds innovative bioabsorbable steroid-eluting sinus implants to ENT portfolio DUBLIN and MENLO PARK, Calif., May 13, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in...

Yahoo Finance

Oct 29th, 2026

Steris vs Medtronic: faster growth and a lower P/E, but Steris has less debt

Medtronic may offer Steris shareholders a cheaper route to faster growth, according to a Trefis comparison. Steris trades at 27.7 times earnings, against 23.2 for Medtronic. Medtronic grew sales 13.7% in fiscal Q1 2027, against 7.3% for Steris. Over twelve months, it grew 9.8%, against 8.4%. On September 1, Medtronic raised its fiscal 2027 organic revenue growth forecast to 7.5% at the midpoint, from 7.0%. Steris keeps the edge on debt, at 9.2% of market value against 23.2%, and on three-year growth, at 9.8% a year against 6.0%. That debt figure predates its agreed $2.1 billion purchase of Xodus Medical. Operating margins are level at about 19%. Steris kept its forecasts but cut its free cash flow forecast to $800 million, from $850 million, to fund a new North Carolina plant.

Yahoo Finance

Oct 28th, 2026

ETFs net buy $18M of Medtronic as IHI leads with $9M, XLV adds $6.1M

Exchange-traded funds (ETFs) bought a net $18.0 million of Medtronic (MDT) on October 26, led by IHI. Twenty-three ETFs added shares, seven sold, and 125 held steady. IHI added 94,888 shares worth $9.0 million, a 2.22% increase in its stake. XLV added 64,258 shares worth $6.1 million, and SPYM bought $0.9 million. The buying followed a net outflow of $6.9 million on October 23 and a net inflow of $9.0 million on October 22. Over the last five reported days, ETFs were net buyers on three. Medtronic has a market cap of $120.2 billion. Trailing 12-month revenue was $37.54 billion, up 9.7% over one year.

NewMediaWire

Oct 26th, 2026

Bronwyn Brophy O'Connor to become CEO of Carl Zeiss Meditec Group in December 2026.

Bronwyn Brophy O'Connor to become CEO of Carl Zeiss Meditec Group in December 2026. Oct. 26, 2026 4:58 PM ET Source: EQS Group AG | International Medtech Executive Brings Extensive Experience in Customer-focused Innovation and Business Transformation JENA and OBERKOCHEN, GERMANY - October 26, 2026 (NEWMEDIAWIRE) - Bronwyn Brophy O'Connor, currently CEO of the Vitrolife Group in Sweden, will take over as CEO of Carl Zeiss Meditec AG on December 1, 2026. On the same date, she will join the Executive Board of Carl Zeiss AG with responsibility for the Medical Technology segment. Her appointment as successor to current CEO Andreas Pecher had been first announced in May 2026. With the start date now confirmed, she will assume leadership of Carl Zeiss Meditec Group from Andreas Pecher, who has served as interim CEO since January 1, 2026. "I am delighted to join Carl Zeiss Meditec and the ZEISS Group. The company combines deep scientific expertise, close customer relationships and a strong commitment to improving patient care. I look forward to working with our teams and customers to build on these strengths, advance innovation and successfully shape the next stage of the company's transformation," said Bronwyn Brophy O'Connor. "With Bronwyn Brophy O'Connor, Carl Zeiss Meditec is gaining an internationally experienced medtech executive who will bring a strong customer and innovation perspective to the company. We wish her a great start," said Peter Kameritsch, Chairman of the Supervisory Board of Carl Zeiss Meditec AG. "We would like to thank Andreas Pecher, both for his temporary dual role as CEO of the ZEISS Group and interim CEO of Carl Zeiss Meditec AG, and for providing important momentum during this period. With her excellent skills, Bronwyn Brophy O'Connor will now be able to further advance the strategy and transformation of the Medical Technology segment forward and contribute to the success of the ZEISS Group," said Dr. Michael Bolle, Chairman of the Supervisory Board of Carl Zeiss AG. Effective December 1, 2026, the Management Board of Carl Zeiss Meditec AG will comprise Bronwyn Brophy O'Connor as CEO and Justus Wehmer as CFO. The Executive Board of Carl Zeiss AG will comprise Andreas Pecher (President and CEO), Stefan Müller (CFO), Bronwyn Brophy O'Connor (Head of the ZEISS Medical Technology segment), Sven Hermann (Head of the ZEISS Consumer Markets segment), Dr. Frank Rohmund (Head of the ZEISS Semiconductor Manufacturing Technology segment), and Dr. Marc Wawerla (Head of the ZEISS Industrial Quality & Research segment). Short profiles: Bronwyn Brophy O'Connor studied at Dublin City University in Ireland. After earning a bachelor's degree in International Marketing and Languages (Spanish and French), she completed her Master of Business Administration in 2002. She started her career at Johnson & Johnson in 1997, serving in roles of increasing seniority and ending her career there as General Manager of the Cardiovascular Care Group for the U.K. & Ireland in 2012. Bronwyn then joined Covidien, which was later acquired by Medtronic to form the largest medtech company globally. From 2013 until 2018, she first served as Vice President Early Technologies EMEA and later as President Women's Health at Medtronic in Boston, USA. In 2019, Bronwyn joined Thermo Fisher Scientific as President for the EMEA region and one year later was promoted to Global President of the Immunodiagnostics Division in Uppsala, Sweden. She has worked internationally, including in Ireland, Spain, the U.K., Switzerland, Sweden and the U.S. Since 2023, Bronwyn Brophy O'Connor has been CEO of the Vitrolife Group, a global medtech company publicly listed on the NASDAQ Stockholm and headquartered in Gothenburg, Sweden. Andreas Pecher studied physics at the University of Würzburg, Germany, and the University of Texas at Austin, USA. He earned a Master of Business Administration (MBA) at the Kellogg School of Management as well as a Master of Engineering Management at the McCormick School of Engineering. He began his career at Motorola (today NXP) in Texas, USA, in 1998. After completing his MBA in 2005, Andreas Pecher worked as a project manager at McKinsey & Company in Germany. Starting in 2010, he headed the Strategy and Business Development department at the solar company Renewable Energy Corporation in Oslo, Norway, and Munich, Germany. In 2013, Andreas Pecher joined the ZEISS Semiconductor Manufacturing Technology (SMT) segment as Head of Strategic Business Development in Oberkochen, Germany. In 2015, he became Head of the Semiconductor Mask Solutions strategic business unit (SMS SBU) and, starting in 2017, headed the Semiconductor Manufacturing Optics strategic business unit. In 2022, Andreas Pecher became Head of the ZEISS SMT segment and was simultaneously appointed a Member of the Executive Board of Carl Zeiss AG. He was named President and CEO of Carl Zeiss AG effective April 1, 2025. In this role, he also took on the interim position as CEO of the publicly listed Carl Zeiss Meditec AG on January 1, 2026, becoming Head of the Medical Technology segment. Contact for investors and the press Sebastian Frericks Head of Group Finance & Investor Relations Carl Zeiss Meditec AG Phone: +49 3641 220-116 Email: [email protected] www.zeiss.com/newsroom About Carl Zeiss Meditec AG Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and SDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,784 employees worldwide, the Group generated revenue of EUR 2,228m in fiscal year 2024/25 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For more information visit its website at www.zeiss.com/med |

AD HOC NEWS

Oct 21st, 2026

FDA recalls Medtronic biopsy kits. Medtronic stock sits 7.04 percent below its high.

FDA recalls Medtronic biopsy kits. Medtronic stock sits 7.04 percent below its high. Published on 10/21/2026 at 10:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS FDA recall covers 3,746 kits on October 17, 2026. Medtronic stock costs EUR 84.36 on October 21, 2026, 7.04 percent below its high. Recall and portfolio changes. * The FDA recall covers 3,746 biopsy kits on October 17, 2026. * First-quarter fiscal 2027 revenue reached USD 9.76 billion, up 13.70 percent year over year. * Medtronic stock trades at EUR 84.36 at 10:33 a.m. CEST at Lang & Schwarz on October 21, 2026. * Medtronic's market capitalization stood at USD 121.0 billion as of October 20, 2026. Medtronic plc (ISIN IE00BTN1Y115) was trading at EUR 84.36 at Lang & Schwarz on October 21, 2026, at 10:33 a.m. CEST, 7.04 percent below its 52-week high of EUR 90.75. The FDA recall of 3,746 biopsy kits is the latest dated company-specific development, according to Boerse Express on October 17, 2026. Discover more Order Takeout Save on Rx Find Gov Offices FDA recall covers 3,746 kits. The Class II recall concerns biopsy needle kits made by Medtronic Navigation, Inc. Material deviations in reflective components can interfere with optical tracking during image-guided procedures. The affected products are used with surgical navigation systems, making the recall relevant to Medtronic's medical-surgical portfolio. The recall report also said Medtronic stock closed at EUR 84.34 on October 16, 2026, after a 1.40 percent decline. That dated move was linked in the report to broad technology-sector selling rather than a company-specific trading trigger. What changed in the portfolio? Medtronic completed the separation of MiniMed in October. The company exchanged 252,813,348 MiniMed shares for 55,032,401 Medtronic ordinary shares, according to Boerse Express. The transaction leaves Medtronic with a different revenue mix and a stronger emphasis on cardiovascular, surgical and neuroscience technologies. Three dated operating milestones. On October 1, 2026, Medtronic announced regulatory approvals for the Altaviva and Symplicity Spyral systems, as listed in the company's Medtronic release archive. On October 7, 2026, it announced a final exchange ratio of 4.5939 for the MiniMed split-off in the same archive. On October 17, 2026, the FDA recall covered 3,746 biopsy kits, according to Boerse Express. Medtronic's first-quarter fiscal 2027 revenue was USD 9.76 billion, up 13.70 percent from the prior-year quarter, while adjusted earnings per share reached USD 1.45 against a USD 1.39 consensus estimate, according to MarketBeat on October 19, 2026. Stock remains below its yearly high. Medtronic's primary listing is on the NYSE, where the stock was last quoted at USD 94.63 on October 20, 2026. Its market capitalization was USD 121.0 billion, and the 52-week range was USD 73.31 to USD 106.33. The recall adds a product-quality issue to a portfolio transition that is otherwise being measured against stronger reported revenue growth. The stock was trading at EUR 84.36 at Lang & Schwarz on October 21, 2026, at 10:33 a.m. CEST, 7.04 percent below its 52-week high of EUR 90.75. The further course of trading is shown by the continuously updated real-time quote of Medtronic stock. Discover more Read Company News Source Med Gear Track Blood Sugar Medtronic stock facts. * Company: Medtronic plc * ISIN: IE00BTN1Y115 * Ticker: MDT * Primary exchange: NYSE * Price Lang & Schwarz (as of October 21, 2026, 10:33 a.m. CEST): EUR 84.36 * 52-week range: USD 73.31-106.33 (as of October 20, 2026) * Market capitalization: USD 121.0 billion (as of October 20, 2026) * Sector / Industry: Healthcare / Medical Devices * Index membership: S&P 500 Sponsored Ad Medtronic stock: new analysis - 24 October. Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | IE00BTN1Y115 | MEDTRONIC PLC | boerse | 70381586 | bgmi